Follow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.
This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.
Approximate Time to Complete: 20 minutes
Course Available Beginning: Oct. 21, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Compare and contrast the utility of immune checkpoint inhibitors with platinum-based doublet or targeted agent-containing regimens
- Incorporate patient- and disease-specific factors in immunotherapy treatment selection in patients with advanced NSCLC
- Identify strategies to avert and manage treatment-related adverse events in patients with advanced NSCLC